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Abstract
In vitro assays could replace animal experiments in drug screening and disease modeling,
but have shortcomings in terms of functional readout. Force-generating engineered heart
tissues (EHT) provide simple automatedmeasurements of contractile function. Here we eval-
uated the response of EHTs to hypoxia/reoxygenation (H/R) and the effect of known cardio-
cytoprotective molecules. EHTs from neonatal rat heart cells were incubated for 24 h in EHT
medium. Then they were subjected to 180 min hypoxia (93%N2, 7%CO2) and 120 min reox-
ygenation (40%O2, 53%N2, 7%CO2), change of medium and additional follow-up of 48 h.
Time-matched controls (40%O2, 53% N2, 7% CO2) were run for comparison. The following
conditions were applied during H/R: fresh EHTmedium (positive control), the NO-donor S-
nitroso-N-acetyl-D,L-penicillamine (SNAP, 10-7, 10-6, 10-5 M) or the guanylate cyclase activa-
tor brain type natriuretic peptide (BNP, 10-9, 10-8, 10-7 M). Frequency and force of contraction
were repeatedly monitored over the entire experiment, pH, troponin I (cTnI), lactate dehydro-
genase (LDH) and glucose concentrations measured in EHTmedium. Beating activity of
EHTs in 24 h-medium ceased during hypoxia, partially recovered during reoxygenation and
reached time-control values during follow-up. H/R was accompanied by a small increase in
LDH and non-significant increase in cTnI. In fresh medium, some EHTs continued beating
during hypoxia and all EHTs recovered faster during reoxygenation. SNAP and BNP showed
small but significant protective effects during reoxygenation. EHTs are applicable to test
potential cardioprotective compounds in vitro, monitoring functional and biochemical end-
points, which otherwise could be only measured by using in vivo or ex vivo heart prepara-
tions. The sensitivity of the model needs improvement.
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Introduction
Ischemic heart disease is the leading cause of death in the industrialized world, therefore, devel-
opment of cardioprotective therapies are of great importance. In vitro drug screening and dis-
ease modeling is a constantly growing research field, since the replacement/minimization of
experimentally sacrificed animals in biomedical research and in the drug development process
is a social and ethical necessity. 3-dimensional engineered heart tissue (EHT) shows typical
phenotypic features of native heart tissue and is applicable to cardiovascular drug screening
[1,2] and modeling of cardiovascular disease such as myocardial hypertrophy [3] and inherited
cardiomyopathies [4]. However, there is limited information on the response of EHT to acute
ischemia/reperfusion [5] and the involvement of cardioprotective signaling pathways that have
been discovered in intact hearts.
Nitric oxide is a well-known cardioprotective molecule, which was extensively studied dur-
ing last decades in different models of ischemia/reperfusion injury and cardioprotection [6].
Besides its vasodilator effect, direct cardiocytoprotection has been previously shown in case of
simulated ischemia (SI) in 2D rat neonatal cardiac myocyte cultures with administration of the
NO-donor S-Nitroso-N-acetyl-D,L-penicillamine (SNAP) [7]. Furthermore, administration of
SNAP has been shown to mimic preconditioning protection in mouse hearts [8]. Concentra-
tion-dependent protection of exogenous NO against simulated ischemia/reperfusion induced
injury was detected in mouse embryonic stem cell-derived cardiomyocytes as well [9]. The
NO-mediated cytoprotection mainly acts via intracellular elevation of cyclic guanosine mono-
phosphate (cGMP), which has a common PKG-dependent downstream signaling pathway
with natriuretic peptides [7,10,11]. B-type natriuretic peptide (BNP), the main natriuretic pep-
tide in ventricular myocardium, has been shown to limit infarct size in rat hearts and protects
neonatal cardiac myocytes against simulated ischemia/reperfusion via activation of
cGMP-PKG pathway [7,10].
Two-dimensional (2D) cardiac myocytes cultures are suitable for the exploration of intra-
cellular mechanisms of cardiocytoprotective agents [12], but information about fundamental
cardiac parameters such as beating rate, contractile force and contraction kinetics remains lim-
ited at best. Moreover 2D neonatal cardiac myocyte cultures are mixed with fibroblasts, of
which the percentage and growing rate is difficult to control and unstable over time. Three-
dimensional (3D) EHT could combine advantages of in vitro and in vivo/ex vivo experimental
setups. The aim of the present study was to evaluate the suitability of EHT as an in vitro model
of hypoxia/reoxygenation injury as well as a screening bed for cardioprotective interventions.
Materials and Methods
Cell isolation and EHT generation
The investigation conforms to the guide for the care and use of laboratory animals published
by the NIH (Publication No. 85–23, revised 1985). Experimental procedures were reviewed
and approved by Ethics Committee, University of Hamburg.
Neonatal rat cardiac myocytes (NRCM) were isolated from 1–3 day old neonates (Wistar
and Lewis rats) and EHTs were generated as previously described [1,13]. In brief, rats were sac-
rificed by decapitation and hearts were digested with a combined enzymatic (DNAse/Trypsin)
and mechanic treatment. EHTs were generated from the unpurified heart cell mix, using a
reconstitution solution as follows (final concentration per ml): 4.1 x 106 cells, 3 U thrombin
(Biopur BP 11-10-1104), 5 mg bovine fibrinogen (Sigma F4753). To yield isotonic conditions,
2xDMEM (20% horse serum, GIBCO 26050; 4% chick embryo extract; 2% penicillin/strepto-
mycin, GIBCO 15140) was added matching the amount of fibrinogen and thrombin. Liquid
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agarose (2% in PBS; Invitrogen 15510–027), custom-made Teflon spacers and 24-well cell cul-
ture plates were used to prepare the casting molds. Silicone attachments (Silitec GmbH & Co.
KG, Weiler-Simmerberg, Germany) with four pairs of silicone posts were placed onto the cast-
ing molds with each pair reaching into a mold. For each EHT 97 μl of the reconstitution mix
was mixed separately with 3 μl thrombin and then pipetted into a mold. After 2 h of incubation
(37°C, 40% O2, 7% CO2) the fibrinogen was polymerized, so that the EHTs could be trans-
ferred to a new, medium-filled (DMEM (Biochrom F0415) with: 10% horse serum, 2% chick
embryo extract, 1% penicillin/streptomycin, insulin (10 μg/ml, Sigma I9278), aprotinin
(33 μg/ml, Sigma A1153) cell culture dish. EHTs were fed every other day and maintained under
cell culture conditions for up to four weeks. EHTs were kept at 40% oxygen throughout their
development because systematic comparisons had shown higher force development at 40% than
at standard 21% oxygen [14]. Experiments were done on EHTs in the period of day 15 to 22.
Contractility measurement
To evaluate the contractile parameters of the EHTs, a setup for video-optical recordings was
used. It consisted of a small cell incubator with controlled humidity, temperature (37°C) and
gas composition (e.g. 40% O2, 7% CO2, 53% N2 for baseline/reoxygenation or 0% O2, 7% CO2,
93% N2 for hypoxia). This cell culture unit had a glass roof with a Basler CCD-camera (Type A
602f-2) mounted on a XYZ-device (IAI Corporation) above. A custom made software (Con-
sulting TeamMachine Vision, ctmv.de; Pforzheim, Germany) allowed to set camera positions
for each EHT in a PC-controlled manner. Light-emitting diodes (LEDs) illuminate the EHTs
during recordings, to which the light exposure was synchronized. The software detected the
EHT at top and bottom end during recordings via a figure recognition mode. Contractile
parameters (e.g. beats per minute, force) were calculated with an equation [15] based on the
elastic modulus of the silicone (1.7 MPa), the geometry of the posts and the post deflection
(delta value of post distance) during the contraction. Reports showing all calculated parameters
were generated by the software automatically.
Hypoxia/reoxygenation
To test EHT responses under ischemic stress, we used hypoxia/reoxygenation to simulate in
vivo myocardial ischemia/reperfusion injury. For this purpose, the spontaneously contracting
15–22 days old EHTs were placed into fresh EHT medium 24 h before experiments. As a pilot
experiment, 4 EHTs were subjected to hypoxia by culturing them in 93% N2 and 7% CO2.
Based on their beating activity the 3 h hypoxic period was chosen for further experiments.
EHTs were subjected to 180 min hypoxia (93% N2 and 7% CO2, EHTs were covered by 24 h
conditioned medium) followed by 120 min of reoxygenation (40% O2 53% N2 and 7% CO2,
EHTs were covered by 24 h conditioned medium). Endpoints were recorded before hypoxia
(baseline), at 11 time points during 180 min hypoxia (0, 15, 30, 45, 60, 80, 100, 120, 140, 160,
180 min) and at 8 time points during reperfusion (0, 20, 40, 60, 75, 90, 105, 120 min). At the
end of experimental protocol the EHT medium was collected, and pH was determined. EHTs
were placed into freshly prepared medium and were incubated further for 48 h. Additional 3
time points were recorded during the follow up period (overnight, 1 day, 2 days). In the end
EHT medium was collected and pH was determined as previously (Fig 1).
Experimental groups
Experimental groups are shown in Fig 1. To demonstrate the effect of simulated hypoxia/reox-
ygenation, EHTs subjected to hypoxia/reoxygenation (named 24 h medium control group;
24 h MC) was compared to the time-matched (normoxic) controls (TMC) that were kept in
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normoxia for 180+120 min. To demonstrate if the response of EHTs to ischemic stress was
affected by known cardiocytoprotective drugs, S-Nitroso-N-acetyl-D,L-penicillamine (SNAP
10−7, 10−6, 10−5 M) (Sigma;St. Louis, MO) or brain type natriuretic peptide-32 (BNP, 10−9,
10−8, 10−7 M) (American Peptides; Sunnyvale, CA) were administered into the 24 h condi-
tioned medium during the 180 min hypoxia and 120 min reoxygenation period.
Cardiac troponin I, lactate dehydrogenase and glucose measurement in
the supernatant
Medium of EHTs was collected at the end of the reoxygenation and follow up period. Cardiac
troponin I (cTnI) concentrations were measured by a double-antibody sandwich enzyme-
linked immunosorbent assay (ELISA) according to the manufacturer's protocol (Life Diagnos-
tics, Inc., 2010-2-HSP). LDH release was measured with an LDH-P kit (Diagnosticum, Buda-
pest, Hungary) with spectrophotometer. LDH release was expressed as U/ml. Glucose content
of medium was measured by a hexokinase assay (Glucose HKMOD P, Roche, R11876899) and
expressed in mmol/L. The pH of EHT medium was checked by pH test strips.
Fig 1. Study design and experimental groups.
doi:10.1371/journal.pone.0132186.g001
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Histological analysis
EHT samples were fixed in 10% neutral buffered formalin prior to paraffin embedding. 5 μm
thick slices were made and stained with hematoxylin-eosin (HE) for the visualization of cellular
structures. The central region of the longitudinally sectioned EHTs was visualized and exam-
ined with a light microscope (Nikon labophot-2) and images were acquired with Olympus
DP71 colour camera using a 40× objective lens. An automatic quantification of nuclei and cel-
lular parameters for estimating apoptosis were obtained from HE-stained sections using the
CellProfiler 2.1.1 image analysis software (Broad Institute). Ten randomly chosen fields from
the central region of each EHT were analyzed for nuclei diameter and area, whereas the area of
parent cytoplasm of each nucleus was also captured and measured.
Statistical analysis
Results are expressed as mean±SEM. The following statistical tests were applied: unpaired t-
test and one way analysis of variance (ANOVA) followed by Dunett’s posthoc test; for multiple
comparisons: multiple t-test and two way analysis of variance (ANOVA) followed by Dunett’s
posthoc test. Differences were considered significant at p<0.05. Chi-squared test was used for
the analysis of the beating map.
Results
Effect of hypoxia/reoxygenation
Spontaneously beating 15–22 days old rat EHTs, incubated for 24 h in EHT medium, were
exposed to 180 min hypoxia and 120 min reoxygenation (24 h medium control; 24 h MC) or
standard 40% oxygen (time-matched control; TMC). The beating map (Fig 2A) shows the con-
tractile activity of EHTs at each recording time point (beating periods are expressed as grey
boxes, non-beating periods are expressed as black boxes). TMC group were essentially stable
during the whole experiment, while hypoxia induced a fast decrease in beating rate and com-
plete cease after ~100 min. Three out of 6 EHTs recovered during reoxygenation and all of
them during the follow up period.
The summary of all beats of each individual EHT (n = 6) at all recording time points showed
a bell-shaped pattern after hypoxia in (Fig 2B) in the 24 h MC group. Time-matched controls
showed a small decline in beating activity during the 5 h long recording period, probably due
to metabolic changes. Hypoxia resulted in a pronounced decrease, while reoxygenation caused
a fast re-initiation of beating rate, which did not reach TMC values during the reoxygenation
period and remained under 20% of the baseline (S1 movie). Since rat EHTs have a negative
force-frequency relationship, frequency multiplied by forces shows less biased results than fre-
quency alone. The rate-force product (beat × force) was also significantly less in the 24 h MC
group than in the TMC group at any stage of reoxygenation (Fig 2C). Follow-up did not show
significant differences between the 24 h MC and TMC groups.
The decreasing nucleus/cytoplasm (N:C) ratio is a widely used cytologic marker for apopto-
sis. Circularity is another marker indicating the severity of apoptosis. N:C ratio and nuclear cir-
cularity did not change in 24 h MC group as compared to TMC group (Fig 2D).
The severity of the hypoxic injury of EHTs was monitored by troponin I and LDH release
into the EHT medium during hypoxia/reoxygenation and follow up (Fig 2E). Glucose con-
sumption was calculated by comparing the concentrations after the intervention with input
concentrations (Fig 2F). The LDH concentration was significantly higher after hypoxia/reoxy-
genation in the 24 h MC group than in the TMC group, while troponin I showed only a ten-
dency, which did not reach significance due to high variability. cTnI concentrations seemed
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also higher in the 24 h MC than in the TMC group after 48 h follow up, but values showed
large variability and no statistical significance. Glucose consumption during hypoxia/reoxygen-
ation was significantly lower than under control conditions, but did not differ during follow
Fig 2. Comparison of EHT contractile behaviour in time-matched control (TMC) and 24 hmedium control (24 h MC) groups (n = 6). (A) Beating
pattern of EHTs was recorded during the entire experiment. Grey boxes indicate beating periods of EHTs, black boxes non-beating phases. (B) Total number
of beats is expressed as the percentage of baseline. (C) Rate force product of EHTs. Data are expressed as mean ± SEM; **p<0.01 multiple t-test, n = 4–6.
(D) Histological analysis of EHT sections (nucleus/cytoplasm ratio, nuclear circularity). (E-F) Biochemical markers of tissue necrosis (cardiac troponin I (cTnI)
and lactate dehydrogenase (LDH) release after hypoxia or after 2 days follow up respectively) and glucose consumption are presented respectively. Data are
expressed as mean ± SEM; *p<0.05; unpaired t-test, n = 4–6.
doi:10.1371/journal.pone.0132186.g002
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up. The pH of the medium was 7.5 after hypoxia/reoxygenation and at follow up in each
group.
Protective effect of fresh medium
We noted in our pilot experiments (data not shown) that fresh medium had protective effects
on EHTs and therefore used it as positive control. In fresh medium, EHTs continued to beat
longer during hypoxia and reoxygenation or recovered quicker under reoxygenation (Chi-
squared test, p<0.05 vs. 24 h MC; Fig 3A). Fresh medium-supplemented EHTs tended to beat
further and restart earlier than the 24 h MC group, but the difference between groups did not
reach statistical significance (Fig 3B).
The protective effect of fresh medium was seen under hypoxia, but was more pronounced
during reoxygenation. Here, the rate-force product was several folds higher than in the 24 h
MC group (Fig 3C). Nucleus/cytoplasm ratio and nuclear circularity, (Fig 3D, S1 Fig) or bio-
chemical markers of tissue necrosis or glucose consumption did not differ between both groups
(Fig 3E and 3F). The pH of the medium was 7.5 after hypoxia/reoxygenation and at follow up
in each group.
Cardiocytoprotective compounds
The NO-donor SNAP or the B-type natriuretic peptide (BNP) were administered at 3 different
concentrations to 24 h medium group before hypoxia/reoxygenation. Both had small, not
clearly concentration-dependent effects on beating behavior of EHTs. None of the compounds
caused significant protective effect during hypoxic phase (S2 and S3 Figs).In the presence of
SNAP (10−7 M) more EHTs tended to beat during reoxygenation than in 24 h MC group
(p = 0.06; Fig 4A). Beating activity (total number of beats; Fig 4B) was higher under SNAP 10−7
and 10−6 M, whereas the rate-force product during first stage of reoxygenation was not signifi-
cantly changed, but during second stage of reoxygenation it was significantly higher under 10−7
and 10−5 M (Fig 4C). SNAP did not affect the N:C ratio (Fig 4D and S1 Fig) or biochemical
markers (Fig 4E and 4F).
BNP did not affect the percentage of beating EHTs (Fig 5A). The sum of all beats (Fig 5B)
and the rate-force product (Fig 5C) were all slightly higher than in the 24 h MC group with a
maximal effect at BNP 10−8 M. The BNP (10−9 M, 10−8 M) treated group showed a significant
increase the N:C ratio and nuclear circularity compared to 24 h MC (Fig 5D and S1 Fig). Bio-
chemical markers and pH values did not differ among the groups (Fig 5E and 5F).
The diameter and length of EHTs were determined at each monitoring points (S4 and S5
Figs). Both, length and diameter of EHTs remained constant during the entire experiment.
Time matched controls
The drop in rate-force product in the TMC group from the first to the second hour was unex-
pected and may be due to technical issues related to moving the 24-well-dish from the incuba-
tor to the set-up for video-optical measurements. None of the treatments had a systematic
effect on any parameter (S6 Fig and S1–S6 Tables).
Discussion
Here we report a novel in vitro model of hypoxia/reoxygenation injury that mimics some con-
ditions of the ischemic heart in a 3-dimensional, tissue-like arrangement of cardiomyocytes
(EHT). (i) EHTs showed a reproducible and fast response to hypoxia and reoxygenation, con-
sisting of cessation of beating under hypoxia and slow recovery under reoxygenation. (ii)
Hypoxia/Reoxygenation Injury in Rat Engineered Heart Tissue
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Hypoxia/reoxygenation in EHTs was associated with moderate LDH release. (iii) Significant
functional recovery was observed after 48 h. (iv) Functional responses to hypoxia/reoxygena-
tion were modified by medium conditions and agonists of the cGMP-PKG pathway that are
known to protect against ischemia/reperfusion injury in other models.
Fig 3. Comparison of EHT contractile behaviour in 24 hmedium control (24 h MC) and freshmedium control (FMC) groups (n = 6). (A) Beating
pattern of EHTs was recorded during the entire experiment. Grey boxes represent beating periods of EHTs whereas black boxes indicate non-beating
phases. Beating pattern was analyzed by Chi square test showing significant differences among these groups (p<0.05). (B) Total number of beats is
expressed as the percentage of baseline. (C) Rate force product of EHTs in 24 h MC and FMC groups during hypoxia and reoxygenation respectively. Data
are expressed as mean ± SEM; *p<0.05; multiple t-test, n = 6. (D) Histological analysis of EHT sections (nucleus/cytoplasm ratio, nuclear circularity). (E-F)
cTnI, LDH release and glucose consumption are shown respectively. Data are expressed as mean ± SEM; unpaired t-test, n = 6.
doi:10.1371/journal.pone.0132186.g003
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Reliable in vitro test models for ischemia/reperfusion injury would be of great interest.
However, available models are difficult to compare to the native heart in terms of histological
features, contractile parameters, physiological and pharmacological responses. Therefore, there
is an unmet need to develop cardiomyocyte-based test-beds for at least medium-throughput
pharmacological screens. Previously, we have reported the responses of neonatal rat cardio-
myocytes [7] and mouse embryonic stem cell-derived cardiomyocytes [9] to different concen-
trations of the NO-donor SNAP and B-type natriuretic peptide. Both test systems show good
reproducibility and high-throughput but respond very differently to hypoxia/reoxygenation
and drugs than the adult heart. For example, the adult heart is highly susceptible to ischemia/
reperfusion injury. Upon global ischemia (less than 5 min) the heart shows no contractile activ-
ity and signs of stunning and hibernation [16]. In contrast, the widely used neonatal cardio-
myocytes are relatively resistant to hypoxia/reoxygenation, therefore longer (minimum 150
min) hypoxia is required to induce cell death in this model [7,17]. In 2D cultures most of the
cells are still alive after 150–240 min of simulated ischemia and continue to contract. They stop
Fig 4. Comparison of EHT contractile behavior in 24 hmedium control (24 h MC) and SNAP treated groups (n = 6). (A) Beating pattern of EHTs. Grey
boxes represent beating periods of EHTs whereas black boxes indicate non-beating phases. (B) Total number of beats is expressed as the percentage of
baseline. (C) Rate force product of EHTs during reoxygenation. (D) Histological parameters of EHT sections. (E-F) cTnI, LDH release and glucose
consumption are shown respectively. Data are expressed as mean ± SEM; **p<0.001 one-way ANOVA, followed by Dunett’s post hoc test, n = 6.
doi:10.1371/journal.pone.0132186.g004
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beating only after longer ischemic period (6–12 h). Embryonic stem cell-derived cardiomyo-
cytes are also relatively resistant to hypoxia/reoxygenation, as we have reported previously [9].
Isolated adult cardiac myocytes show an intermediate phenotype. Qui et al showed that iso-
lated rat cardiac myocytes have a reduced contractile function after 180 min ischemia [18] Fur-
thermore, they showed this ischemic insult resulted in 70% cell death. Moreover, others have
shown that isolated mouse ventricular myocytes are vulnerable for a 40 min ischemic insult
and 50% of cells are apparently dead after 18 h reperfusion [19]. Isolated human cardiac myo-
cytes are still contracting after isolation, too as well [20].
The data suggest that the degree of hypoxia-resistance reflects the developmental stage of
the cells. Newborn rat survive up to 30 min in pure CO2 (ie, hypoxia and hypercapnia),
whereas 10-day-old rats die after 5 min [21]. The fact that EHTs stopped beating quickly after
the onset of hypoxia, needed several hours to fully recover after 180 min hypoxia and showed
some increases in LDH indicates that this preparation has a higher maturity than 2D neonatal
rat cardiac myocytes. On the other hand, they are still much less sensitive than adult cardiac
myocytes. Glucose consumption rate, a measure of metabolic activity, correlated well with the
Fig 5. Comparison of EHT contractile behavior in 24 hmedium control (24 h MC) and BNP treated groups (n = 6). (A) Beating pattern of EHTs. Grey
boxes indicate beating periods of EHTs whereas black boxes show non-beating phases. (B) Total number of beats is expressed as the percentage of
baseline. (C) Rate force product of EHTs during reoxygenation. (D) Histological parameters of EHT sections are visible. (E) cTnI and LDH release. (F)
Glucose consumption. Data are expressed as mean ± SEM; **p<0.001 one-way ANOVA, followed by Dunett’s post hoc test, n = 6.
doi:10.1371/journal.pone.0132186.g005
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amplitude of contraction in artificial heart tissue constructs [22]. EHTs showed a higher sensi-
tivity to the hypoxic insult than neonatal rat heart cells cultured in 2D [7], indicating more aer-
obic glucose metabolism.
Besides the functional and biochemical parameters, signs of mild hypoxic injury, like mor-
phologic parameters (ie, nuclear circularity, N:C ratio) were evaluated in this study. Morpho-
logic hallmarks of apoptosis including chromatic margination, nuclear condensation and
fragmentation, which are early events in cell death [23]. This process is then followed by the
fragmentation of cell membrane and release of numerous intracellular substances (ie, LDH)
[24]. However, the mixed cell population of EHTs was evaluated in this study, as the hypoxic
response of full EHTs were in the focus. The morphological pattern of EHTs varies from the
edge to the central region [25] and moderately ischemic central regions did not show early
signs of apoptosis. Interestingly, we observed that simulated ischemia (combination of low pH-
solution and hypoxia) stopped beating activity of EHT during the first 15 min without any
recovery during reoxygenation (data not shown). The mechanisms of different hypoxia resis-
tance likely a different dependency on oxidative mitochondrial metabolism, but more work is
needed to answer this question.
Besides the differences in cell death caused by hypoxia/reoxygenation injury, there are
notable differences in the response to various drug treatments. Both the NO- and the BNP-
dependent cGMP-PKG pathways exerted remarkable cardioprotection in animal models of
ischemia/reperfusion injury [10,26]. The cardioprotective importance of these pathways was
also evidenced in neonatal cardiomyocytes [7], but only NO-dependent protection was detect-
able in mouse embryonic stem cell-derived cardiomyocytes [9]. In the present study, we
describe moderate protection of EHTs against hypoxia/reoxygenation-induced stunning by
NO and BNP. Both treatments induced apparent cardioprotection that was detected as a main-
tained contractile activity and inotropy. In the present study, SNAP significantly increased rate
force product values at 10−7 M and 10−5 M, but not at 10−6 M during reoxygenation. The lack
of significant protective effect of 10−6 M could be simply due to biological variations of the
EHTs. However, the majority of studies failed to observe clear concentration-response relation-
ships of NO donors including SNAP (see for reviews: [6,27]). This phenomenon may be due to
the fact that local tissue NO concentrations largely depend on the ratio of NO and local super-
oxide production. The protection afforded by SNAP was more pronounced in comparison to
BNP in the present study, which is in line with previous literature data obtained in conven-
tional cellular models [28]. NO donors also attenuated the harmful effects of stunning, an effect
comparable to that of late preconditioning [29,30]. In the present study, the protective effect of
BNP showed a bell-shaped concentration-response curve with a maximum protection obtained
at 10−8 M during reoxygenation. Bell-shaped concentration-response curves can be frequently
observed with other cardiocytoprotective compounds, such as e.g. biglycan in neonatal rat car-
diac myocytes [17] or SNAP in mice in vivo [31]. A similar observation was described by Bur-
ley and Baxter, showing that BNP at 10−8 M administered during reperfusion in isolated rat
hearts is cardioprotective [10].
A notable limitation of the present study is that the degree of hypoxia/reoxygenation-
induced injury as well as the protective effects of drugs was moderate. LDH, an indicator of cell
death, only modestly increased after extended hypoxia/reoxygenation and contractile function
fully recovered after 48 h. The magnitude of functional alterations (rate force product, time to
first stop) did not correlate with necrosis and apoptosis markers, probably due to small differ-
ences between individual EHTs and the mild degree of hypoxic stimulus. Future work should
be directed towards improved cellular maturation to increase the sensitivity of the assay to a
level better comparable with adult hearts. Moreover, more harmful conditions should be
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found, so that the EHTs show a higher degree of injury and thereby give the opportunity to res-
cue function/biochemical parameters in a larger range.
Taken together we have shown for the first time that EHTs can be utilized as an experimen-
tal in vitro model for hypoxia/reoxygenation injury and cardioprotective drug treatment.
Advantages compared to existing in vitro models are the possibility to monitor several parame-
ters of contractile function under highly controlled conditions and, perspectively, to switch to a
human, pluripotent stem cell-derived EHT model.
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(TIF)
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